Brian's Dream Diary - Over 8,000 documented dreams, many of which have already come true :: Brian Ladd specializes in dream analyzation, dream prediction, remote viewing and more with thousands of documeneted dreams that have come true...the largest personal online dream diary in the world. Brian does not claim to be psychic, he insists we all can predict the future using our dreams, and much, much more.

As of Friday, September 08, 2006 20:39:05 -0400 this is what we have on this specific dream drawing prediction. If your able to help provide proof or information on this specific drawing, please click here to send me an email. Please include the exact date of the dream or the DD number. And again, thank you for your time, its very much appreciated.

Is this the big drug maker Glaxo Smith-Kline? If so, I wonder if I should buy some shares. I don't suppose you know yet what is going to make their share price go up like that, do you? Thanks for the possible tip.

Hi, I did some checking and it is a stock, and it is the drug maker. Would suggest that you do, but it could be risky.

LONDON, Mar 30, 2006 (AP Online via COMTEX) -- Pharmaceutical company GlaxoSmithKline PLC said Thursday it has begun international clinical trials of two pandemic vaccines against the H5N1 strain of bird flu in humans.

Glaxo said preliminary results from the trials would be available in the third quarter _ supporting its plan to begin production of a vaccine later this year.

The company said its planned initial clinical trials for influenza vaccines based on cell cultures, instead of eggs, could speed up production time.

Glaxo is currently testing the ability of vaccines to boost immune response against bird flu. The company is also trying to reduce the amount of the key ingredient in the vaccine to allow for greater production in case of a pandemic.

Public health experts fear that the H5N1 virus _ which is circulating in bird populations around the world, prompting authorities to destroy more than 200 million birds _ may evolve into a strain that is easily transmitted from human to human, triggering a worldwide pandemic. The virus has already killed 105 people in nine countries, but virtually all were infected by close contact with sick poultry.

Glaxo's trial of 400 healthy adults in Germany tests a vaccine made with a classic adjuvant, or additive, to improve human immunity response. Another trial of 400 more volunteers in Belgium involves a new adjuvant, which reduces the amount of antigen, or active ingredient, per dose.

Using the minimum amount of antigen to produce the maximum number of shots is a key challenge in the race to develop a potential vaccine because it would help stretch supplies in the event of a pandemic.

"While the first vaccine candidate aims at mounting a strong defense against a pandemic outbreak, the second vaccine may offer governments a preferred option to proactively stockpile and begin vaccination before the onset of a pandemic," said Jean Stephenne, President of GSK Biologicals, the vaccine division of Glaxo.

However, Glaxo acknowledged that its vaccines were being tested at lower doses than a U.S. vaccine that showed only modest effects in early testing.

Glaxo said its test shots _ taken in pairs over a period of months _ each contain a range of just under 4 micrograms to 30 micrograms of antigen.

Results of the first human testing in the United States of an H5N1 vaccine, published Thursday in The New England Journal of Medicine, found that it took two shots of 90 micrograms of antigen each to spur a protective immune response in slightly over half of recipients.

Ripley Ballou, vice president of clinical R&D at Glaxo, said the company remained confident about its chosen range and that "one of the two antigens would be successful in eliciting superior immune responses."

Bruce Innis, director of clinical R&D and medical affairs for Glaxo vaccines for virus diseases in North America, added that a switch to cell culture trials from the 30-year-old method of producing flu vaccines inside chicken eggs would allow large-scale manufacturing of vaccines.

"We cannot say today when we are ready to file for approval, but the first clinical trial will occur sometime this year," Innis said. "This is a medium to long-term solution for capacity issues."

Glaxo is one of several companies, including Sanofi-Aventis SA and Chiron Corp., working to develop a vaccine against the H5N1 strain of bird flu. Experts say there is no guarantee that pandemic vaccines developed now will match any pandemic flu strain, but acknowledge they could "prime" the human immune system for an attack.

Glaxo has already submitted a "mock-up" dossier to European health-care regulators seeking clearance to market a vaccine against pandemic flu, the first manufacturer to do so under new EU rules designed to fast-track approval.

Shares in GlaxoSmithKline rose 0.4 percent to 1,509 pence ($26.33) on the London Stock Exchange.

Brian , On Mar. 29 you had a dream in which GSK hit $206.25 on 12-16-06.

This is Glaxo Smith Klein which is around $54. right now.

Do you think this will happen , can you remote it ?

Ken

reply

Hi Ken, you do not need to pay for this, I do think it will reach that amount per share.

Brian